Hydrochlorothiazide

Hydrochlorothiazide (HCTZ), an orally active diuretic agent of the thiazide class, inhibits transforming TGF-β/Smad signaling pathway. Hydrochlorothiazide has direct vascular relaxant effects via opening of the calcium-activated potassium (KCA) channel. Hydrochlorothiazide improves cardiac function, reduces fibrosis and has antihypertensive effect[1][2][3].

Product Specifications

CAS Number

[58-93-5]

Product Name Alternative

HCTZ

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Potassium Channel; TGF-beta/Smad

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Stem Cell/Wnt; TGF-beta/Smad

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Hydrochlorothiazide.html

Purity

99.46

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=S(C1=C(Cl)C=C(C2=C1)NCNS2(=O)=O)(N)=O

Molecular Formula

C7H8ClN3O4S2

Molecular Weight

297.75

Precautions

H302, H315, H319, H335

References & Citations

[1]Duarte, J.D. and R.M. Cooper-DeHoff, Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics. Expert Rev Cardiovasc Ther, 2010. 8 (6) : p. 793-802.|[2]Magdy M Abdelquader, et al. Inhibition of Co-Crystallization of Olmesartan Medoxomil and Hydrochlorothiazide for Enhanced Dissolution Rate in Their Fixed Dose Combination. AAPS PharmSciTech. 2018 Dec 17;20 (1) :3.|[3]Jinghong Luo, et al. Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats. Cardiovasc Ther. 2017 Apr;35 (2) .